Anebulo faces Nasdaq delisting risk after change of control; enters lock-up with 22NW

Anebulo Pharmaceuticals, Inc.

Nasdaq determined that Dec 2024 private placement caused a change of control, violating Listing Rule 5635(b); company received notice Feb 20, 2025.
Company entered lock-up agreement with 22NW (Aron English) on Feb 24, 2025, restricting voting/sale of 10.1M shares until stockholder approval.
Nasdaq granted extension until April 10, 2025 to obtain stockholder approval; annual meeting scheduled April 4, 2025.
Joseph Lawler entities have agreed to vote in favor of removing lock-up restrictions, which would ratify the change of control.
Failure to obtain stockholder approval by April 10, 2025 may result in delisting from Nasdaq Capital Market.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.